Skip to main content
Journal cover image

Rifampin use and safety in hospitalized infants.

Publication ,  Journal Article
Arnold, CJ; Ericson, J; Kohman, J; Corey, KL; Oh, M; Onabanjo, J; Hornik, CP; Clark, RH; Benjamin, DK; Smith, PB; Chu, VH ...
Published in: Am J Perinatol
May 2015

OBJECTIVE: This study aims to examine the use and safety of rifampin in the hospitalized infants. STUDY DESIGN: Observational study of clinical and laboratory adverse events among infants exposed to rifampin from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012. RESULT: Overall, 2,500 infants received 4,279 courses of rifampin; mean gestational age was 27 weeks (5th, 95th percentile; 23, 36) and mean birth weight was 1,125 g (515; 2,830). Thrombocytopenia (121/1,000 infant days) and conjugated hyperbilirubinemia (25/1,000 infant days) were the most common laboratory adverse events. The most common clinical adverse events were medical necrotizing enterocolitis (64/2,500 infants, 3%) and seizure (60/2,500 infants, 2%). CONCLUSION: The overall incidence of adverse events among infants receiving rifampin appears low; however, additional studies to further evaluate safety and dosing of rifampin in this population are needed.

Duke Scholars

Published In

Am J Perinatol

DOI

EISSN

1098-8785

Publication Date

May 2015

Volume

32

Issue

6

Start / End Page

565 / 570

Location

United States

Related Subject Headings

  • Thrombocytopenia
  • Seizures
  • Rifampin
  • Obstetrics & Reproductive Medicine
  • Male
  • Intensive Care Units, Neonatal
  • Infant, Very Low Birth Weight
  • Infant, Newborn
  • Infant, Extremely Premature
  • Infant
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Arnold, C. J., Ericson, J., Kohman, J., Corey, K. L., Oh, M., Onabanjo, J., … Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee, . (2015). Rifampin use and safety in hospitalized infants. Am J Perinatol, 32(6), 565–570. https://doi.org/10.1055/s-0034-1543955
Arnold, Christopher J., Jessica Ericson, Jordan Kohman, Kaitlyn L. Corey, Morgan Oh, Janet Onabanjo, Christoph P. Hornik, et al. “Rifampin use and safety in hospitalized infants.Am J Perinatol 32, no. 6 (May 2015): 565–70. https://doi.org/10.1055/s-0034-1543955.
Arnold CJ, Ericson J, Kohman J, Corey KL, Oh M, Onabanjo J, et al. Rifampin use and safety in hospitalized infants. Am J Perinatol. 2015 May;32(6):565–70.
Arnold, Christopher J., et al. “Rifampin use and safety in hospitalized infants.Am J Perinatol, vol. 32, no. 6, May 2015, pp. 565–70. Pubmed, doi:10.1055/s-0034-1543955.
Arnold CJ, Ericson J, Kohman J, Corey KL, Oh M, Onabanjo J, Hornik CP, Clark RH, Benjamin DK, Smith PB, Chu VH, Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee. Rifampin use and safety in hospitalized infants. Am J Perinatol. 2015 May;32(6):565–570.
Journal cover image

Published In

Am J Perinatol

DOI

EISSN

1098-8785

Publication Date

May 2015

Volume

32

Issue

6

Start / End Page

565 / 570

Location

United States

Related Subject Headings

  • Thrombocytopenia
  • Seizures
  • Rifampin
  • Obstetrics & Reproductive Medicine
  • Male
  • Intensive Care Units, Neonatal
  • Infant, Very Low Birth Weight
  • Infant, Newborn
  • Infant, Extremely Premature
  • Infant